AbstractLacosamide is a new antiepileptic drug that has been successfully used for the treatment of partial seizures. We report three neurosurgical cases of simple partial status epilepticus refractory to multiple antiepileptic medications. The addition of oral lacosamide in doses of 200–400mg in combination with the existing treatment had successfully controlled the seizures within four days
Objective: A unicentre, prospective study was carried out to investigate the behavioral effects of l...
: Efficacy, safety and tolerability of lacosamide in the treatment of status epilepticus are well de...
INTRODUCTION: To evaluate the ef?cacy and safety of lacosamide (200-300-400 mg/day) as adjunctive tr...
AbstractLacosamide has been reported to have been successfully used for non-convulsive status epilep...
AbstractProlonged, refractory status epilepticus is a rare clinical syndrome that is associated with...
AbstractProlonged, refractory status epilepticus is a rare clinical syndrome that is associated with...
AbstractBackgroundMany patients present with refractory Status epilepticus (SE) despite multiple ant...
AbstractNonconvulsive status epilepticus (NCSE) and epilepsia partialis continua (EPC) are common ep...
AbstractIntroductionLacosamide (LCS) is a new antiepileptic drug (AED) licensed in the European Unio...
AbstractThis retrospective study reports the early experience with lacosamide (LCM) as adjunctive th...
AbstractPurposeTo review the evidence for efficacy and safety of lacosamide in adult patients with r...
AbstractPurposeTo evaluate the efficacy and safety of lacosamide administered as either first add-on...
tients remain seizure-free after initiating a single antiepileptic drug (AED), and 37 % of patients ...
AbstractObjectives: The study was carried out to investigate the safety of lacosamide on children wi...
Background. The relative efficacy and safety of lacosamide as adjunctive therapy compared to other a...
Objective: A unicentre, prospective study was carried out to investigate the behavioral effects of l...
: Efficacy, safety and tolerability of lacosamide in the treatment of status epilepticus are well de...
INTRODUCTION: To evaluate the ef?cacy and safety of lacosamide (200-300-400 mg/day) as adjunctive tr...
AbstractLacosamide has been reported to have been successfully used for non-convulsive status epilep...
AbstractProlonged, refractory status epilepticus is a rare clinical syndrome that is associated with...
AbstractProlonged, refractory status epilepticus is a rare clinical syndrome that is associated with...
AbstractBackgroundMany patients present with refractory Status epilepticus (SE) despite multiple ant...
AbstractNonconvulsive status epilepticus (NCSE) and epilepsia partialis continua (EPC) are common ep...
AbstractIntroductionLacosamide (LCS) is a new antiepileptic drug (AED) licensed in the European Unio...
AbstractThis retrospective study reports the early experience with lacosamide (LCM) as adjunctive th...
AbstractPurposeTo review the evidence for efficacy and safety of lacosamide in adult patients with r...
AbstractPurposeTo evaluate the efficacy and safety of lacosamide administered as either first add-on...
tients remain seizure-free after initiating a single antiepileptic drug (AED), and 37 % of patients ...
AbstractObjectives: The study was carried out to investigate the safety of lacosamide on children wi...
Background. The relative efficacy and safety of lacosamide as adjunctive therapy compared to other a...
Objective: A unicentre, prospective study was carried out to investigate the behavioral effects of l...
: Efficacy, safety and tolerability of lacosamide in the treatment of status epilepticus are well de...
INTRODUCTION: To evaluate the ef?cacy and safety of lacosamide (200-300-400 mg/day) as adjunctive tr...